tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

TVTX Stock Latest News

Target initiated, Nike upgraded: Wall Street’s top analyst calls
The FlyTarget initiated, Nike upgraded: Wall Street’s top analyst calls
8h ago
DG
HD
Travere Therapeutics price target raised to $25 from $20 at Stifel
PremiumThe Fly
Travere Therapeutics price target raised to $25 from $20 at Stifel
6d ago
TVTX
Travere Therapeutics falls -6.6%
PremiumThe Fly
Travere Therapeutics falls -6.6%
7d ago
TVTX
Travere Therapeutics price target raised to $35 from $27 at Wells Fargo
PremiumThe Fly
Travere Therapeutics price target raised to $35 from $27 at Wells Fargo
7d ago
TVTX
Oracle surges on cloud outlook, Novo to cut 9,000 jobs: Morning Buzz
PremiumThe Fly
Oracle surges on cloud outlook, Novo to cut 9,000 jobs: Morning Buzz
8d ago
ATI
HPQ
Positive Outlook for Travere Therapeutics: Buy Rating Supported by FILSPARI’s Strong Data and Competitive Advantages
PremiumRatingsPositive Outlook for Travere Therapeutics: Buy Rating Supported by FILSPARI’s Strong Data and Competitive Advantages
8d ago
TVTX
AdCom cancellation ‘clear positive’ for Travere Therapeutics, says Jefferies
Premium
The Fly
AdCom cancellation ‘clear positive’ for Travere Therapeutics, says Jefferies
8d ago
TVTX
FDA reversing course on adcomm should reassure Travere investors, says BofA
Premium
The Fly
FDA reversing course on adcomm should reassure Travere investors, says BofA
8d ago
TVTX
FDA Drops Advisory Committee for Travere’s FILSPARI Review
PremiumCompany Announcements
FDA Drops Advisory Committee for Travere’s FILSPARI Review
8d ago
8K
TVTX
FDA says advisory committee no longer needed for Travere Filspari sNDA
PremiumThe Fly
FDA says advisory committee no longer needed for Travere Filspari sNDA
8d ago
TVTX
Optimistic Outlook for Travere Therapeutics Driven by Regulatory Advancements and Market Opportunities
PremiumRatings
Optimistic Outlook for Travere Therapeutics Driven by Regulatory Advancements and Market Opportunities
18d ago
TVTX
Nvidia reports Q2 beat, Snowflake posts ‘beat and raise’: Morning Buzz
PremiumThe Fly
Nvidia reports Q2 beat, Snowflake posts ‘beat and raise’: Morning Buzz
21d ago
F
DG
Ligand price target raised to $206 from $157 at H.C. Wainwright
PremiumThe FlyLigand price target raised to $206 from $157 at H.C. Wainwright
21d ago
LGND
TVTX
Travere Therapeutics price target raised to $47 from $30 at H.C. Wainwright
Premium
The Fly
Travere Therapeutics price target raised to $47 from $30 at H.C. Wainwright
21d ago
TVTX
Buy Rating Affirmed for Travere Therapeutics Amid Positive FDA Changes for Filspari
Premium
Ratings
Buy Rating Affirmed for Travere Therapeutics Amid Positive FDA Changes for Filspari
21d ago
TVTX
Travere Therapeutics’ filspari granted FDA approval for REMS labeling
PremiumThe Fly
Travere Therapeutics’ filspari granted FDA approval for REMS labeling
22d ago
TVTX
Strategic Positioning and Growth Potential Drive Buy Rating for Travere Therapeutics
PremiumRatings
Strategic Positioning and Growth Potential Drive Buy Rating for Travere Therapeutics
1M ago
TVTX
Positive Growth Outlook for Travere Therapeutics Driven by Filspari’s Market Potential and Strategic Initiatives
PremiumRatings
Positive Growth Outlook for Travere Therapeutics Driven by Filspari’s Market Potential and Strategic Initiatives
1M ago
TVTX
Travere Therapeutics price target raised to $34 from $32 at Citi
PremiumThe Fly
Travere Therapeutics price target raised to $34 from $32 at Citi
1M ago
TVTX
Strong Sales Performance and Market Expansion Potential Drive Buy Rating for Travere Therapeutics
PremiumRatingsStrong Sales Performance and Market Expansion Potential Drive Buy Rating for Travere Therapeutics
1M ago
TVTX
Travere Therapeutics Earnings Call Highlights FILSPARI Success
Premium
Company Announcements
Travere Therapeutics Earnings Call Highlights FILSPARI Success
1M ago
TVTX
Travere Therapeutics price target raised to $31 from $30 at Scotiabank
Premium
The Fly
Travere Therapeutics price target raised to $31 from $30 at Scotiabank
1M ago
TVTX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >